Raff

Raff Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation, conditionally active biologics for oncology and immunology. Founded by world-renowned immunologist Richard A. Flavell, the company leverages a proprietary platform to engineer therapeutic proteins that remain inert in systemic circulation but activate specifically within the disease microenvironment. This localized activation is designed to maximize therapeutic potency while significantly reducing the systemic toxicities often associated with traditional cytokine and antibody therapies. Currently, the company is advancing a pipeline of "smart" biologics through early-stage development to address unmet needs in cancer and inflammatory disorders. Raff Therapeutics is headquartered in New Haven, Connecticut, and is backed by leading life science venture capital firms.